Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 69.11% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.20M.
Fairly Valued
The company’s latest PE is -0.61, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.25M shares, increasing 33.51% quarter-over-quarter.